<html>
 <body>
  <div class="col-md-12" id="content" style="">
   <div class="hidden" data-drupal-messages-fallback="">
   </div>
   <div class="widget block" id="block-medsites-page-title">
    <h1>
     <span property="schema:name">
      Chemotherapy Toxicity
     </span>
    </h1>
   </div>
   <div class="widget block" id="block-medsites-content">
    <article about="/commodorecompendium/chemotherapy-toxicity" data-history-node-id="1034" role="article" typeof="schema:WebPage">
     <div>
      <div class="field field--name-body field--type-text-with-summary field--label-hidden field__item" property="schema:text">
       <div class="WordSection1">
        <div style="border-bottom:solid windowtext 1.0pt; border-top:double windowtext 1.5pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Chemotherapy Toxicities - Beau Hilton
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                The role of Intern/Resident on the Hematology/Oncology services is largely to work with the fellow to monitor and manage adverse effects of chemotherapy
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Concerns about specific immune-related adverse event: refer to “Toxicities associated with checkpoint inhibitor immunotherapy,” on UpToDate
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:#201f1e">
                  Treatment of immune checkpoint inhibitor toxicities: “Management of Immunotherapy-Related Toxicities” in the NCCN Guidelines for Supportive Care section
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p style="margin-left:25px">
        </p>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="background:white">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Neutropenia:
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Chemotherapy-associated: usually 5-18 days after treatment
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Cancer infiltrate of bone marrow
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  New occult infection: especially EBV, CMV
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Patients can be safely discharged with ANC > 500
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="background:white">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Mucositis:
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Worst in pts receiving concurrent radiation to head and neck, rectum, prostate
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Begins shortly after chemo dose, usually peaks on day 7
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  High risk: bleomycin, cytarabine, anthracyclines, etoposide, 5-FU, methotrexate
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="background:white">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Treatment: “Salt and soda” rinses (1 tsp salt, 1 tsp baking sode in 1-quart water, swish and spit 5 times per day), viscous lidocaine, capsaicin candy, Magic Mouthwash
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Immune Checkpoint Inhibitor Toxicities:
               </span>
              </span>
             </b>
            </span>
           </span>
          </span>
         </span>
        </p>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Treatment: low-dose glucocorticoids (prednisone, 0.5 mg/kg) for mild adverse events, high dose glucocorticoids (prednisone, 1-2 mg/kg) for severe adverse events
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <table class="Table" style="width:347px; border-collapse:collapse; border:none" width="347">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Adverse Event Type</td>
      <td>Incidence with anti-CTLA-4 (ipilimumab)</td>
      <td>Incidence with anti‐PD1/PD‐L1 (nivolumab, pembrolizumab)</td>
    </tr>
    <tr>
      <td>Skin (pruritus, acne, TEN)</td>
      <td>30%</td>
      <td>30%</td>
    </tr>
    <tr>
      <td>Colitis</td>
      <td>25%</td>
      <td>5%</td>
    </tr>
    <tr>
      <td>Hypothyroidism</td>
      <td>20%</td>
      <td>20%</td>
    </tr>
    <tr>
      <td>Hepatitis</td>
      <td>10%</td>
      <td>1%</td>
    </tr>
    <tr>
      <td>Hypophysitis</td>
      <td>10%</td>
      <td>rare</td>
    </tr>
    <tr>
      <td>Pneumonitis</td>
      <td>2-5%</td>
      <td>2-5%</td>
    </tr>
    <tr>
      <td>Myocarditis (fatality&gt;25%)</td>
      <td>&lt;1%</td>
      <td>&lt;1%</td>
    </tr>
    <tr>
      <td>Neurotoxicity (GBS, myasthenia gravis, encephalitis)</td>
      <td>&lt;1%</td>
      <td>&lt;1%</td>
    </tr>
  </tbody>
</table>
        </table>
       </div>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <b>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Chemotherapeutic Agent
             </span>
            </span>
           </b>
           <b>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Toxicities
             </span>
            </span>
           </b>
          </span>
         </span>
        </span>
       </p>
       <table class="Table" style="width:100.0%; border-collapse:collapse; border:none" width="100%">
        <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Organ System</th>
      <th>Agent</th>
      <th>Side Effect</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Alkylating Agents</td>
      <td>Busulfan</td>
      <td>Pulmonary fibrosis or diffuse alveolar hemorrhage (8%)</td>
    </tr>
    <tr>
      <td>Alkylating Agents</td>
      <td>Cyclophosphamide</td>
      <td>Myopericarditis. Hemorrhagic cystitis (prevention: hydration; monitoring: daily UA, Tx: Mesna</td>
    </tr>
    <tr>
      <td>Alkylating Agents</td>
      <td>Ifosfamide</td>
      <td>Encephalopathy (tx: methylene blue)</td>
    </tr>
    <tr>
      <td>Antimetabolites</td>
      <td>5- Fluorouracil (5-FU)/ Capecitabine (metabolized to FU)</td>
      <td>Coronary vasospasm (ppx: CCB); palmar-plantar erythrodysesthesia</td>
    </tr>
    <tr>
      <td>Antimetabolites</td>
      <td>Cladribine, pentostatin</td>
      <td>Dose reduced for CrCl</td>
    </tr>
    <tr>
      <td>Antimetabolites</td>
      <td>Cytarabine (Ara-C)</td>
      <td>Irreversible cerebellar ataxia (if high dose, neuro checks required). Conjunctivitis (prevent with prophylactic steroid eye drops)</td>
    </tr>
    <tr>
      <td>Antimetabolites</td>
      <td>Gemcitabine</td>
      <td>Transient transaminitis. Decrease dose only if hyperbilirubinemia.</td>
    </tr>
    <tr>
      <td>Antimetabolites</td>
      <td>Methotrexate</td>
      <td>Hepatotoxicity, renal failure, high dose requires leucovorin</td>
    </tr>
    <tr>
      <td>Antitumor antibiotics</td>
      <td>Anthracyclines (doxorubicin, duanorubicin, idarubicin)</td>
      <td>HFrEF (need TTE prior). Most notable with doxorubicin.</td>
    </tr>
    <tr>
      <td>Antitumor antibiotics</td>
      <td>Bleomycin</td>
      <td>Pulmonary fibrosis (10%). Potentiated with G-CSF</td>
    </tr>
    <tr>
      <td>Monoclonal Antibodies</td>
      <td>Alemtuzumab</td>
      <td>Severe and prolonged cytopenias</td>
    </tr>
    <tr>
      <td>Monoclonal Antibodies</td>
      <td>Bevacizumab</td>
      <td>HFrEF, HTN, hyperglycemia, hypomag, DVT, pulm hemorrhage</td>
    </tr>
    <tr>
      <td>Monoclonal Antibodies</td>
      <td>Rituximab</td>
      <td>Hypophos, hepatotoxicity, HBV reactivation (screen all patients), peripheral neuropathy</td>
    </tr>
    <tr>
      <td>Platinum Agents</td>
      <td>Cisplatin, oxaliplatin, carboplatin</td>
      <td>Nephrotoxicity, worst with cisplatin. Rental tubular acidosis. Neurotoxicity- &gt;85% oxaliplatin (parasthesias, cold sensitivity, cramps), neuropathy, ototoxicity</td>
    </tr>
    <tr>
      <td>Taxanes</td>
      <td>Docetaxel, paclitaxel</td>
      <td>Hypersensivitivy reaction. Often require premedication with steroids and H1/H2 blockers.</td>
    </tr>
    <tr>
      <td>Topoisomerase Inhibitors</td>
      <td>Irinotecan, topotecan, etoposide</td>
      <td>Irinotecan- acute diarrhea can be treated with atropine</td>
    </tr>
    <tr>
      <td>Tyrosine Kinase Inhibitors</td>
      <td>Imatinib, Dasatinib, Nilotinib, Bosutinib</td>
      <td>Qtc prolongation, pulmonary effusion, hepatotoxicity</td>
    </tr>
    <tr>
      <td>Vinca alkaloid</td>
      <td>Vincristine</td>
      <td>Peripheral neuropathy and ototoxicity (vestibular system lost first)</td>
    </tr>
  </tbody>
</table>
       </table>
      </div>
     </div>
    </article>
   </div>
  </div>
 </body>
</html>